Payment overview · 2025
General Payments
$375.84
13 reported records · 8 companies
Healthcare provider profile · identity verified
Rajeev Rajani, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NAPLES, FL · NPI 1316038698
Verified facts
What the public records show
CMS Open Payments records show Rajeev Rajani, M.D. received $375.84 in general payments during 2025 across 13 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $119.08 | 31.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.54 | 20.6% | 4 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $46.38 | 12.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.44 | 12.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.94 | 7.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.04 | 6.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.74 | 5.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.68 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $375.84 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $119.08 | 2 | 2025 |
Source payment records
|
|||||
| SIMPLIMAX Normalized: simplimax |
Medical Supply | Organogenesis Inc. | $46.38 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.20 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
44 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 878 | 257 |
| Levothyroxine Sodium | Levothyroxine Sodium | 839 | 235 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 663 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 585 | 184 |
| Metformin Hcl | Metformin Hcl | 493 | 156 |
| Losartan Potassium | Losartan Potassium | 467 | 141 |
| Lisinopril | Lisinopril | 395 | 123 |
| Metoprolol Succinate | Metoprolol Succinate | 378 | 118 |
| Omeprazole | Omeprazole | 374 | 132 |
| Simvastatin | Simvastatin | 312 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 303 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 197 | 79 |
| Allopurinol | Allopurinol | 191 | 60 |
| Gabapentin | Gabapentin | 184 | 54 |
| Furosemide | Furosemide | 173 | 68 |
| Tramadol Hcl | Tramadol Hcl | 164 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 60 |
| Potassium Chloride | Potassium Chloride | 156 | 63 |
| Alprazolam | Alprazolam | 153 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 50 |
| Valsartan | Valsartan | 149 | 43 |
| Sertraline Hcl | Sertraline Hcl | 145 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 37 |
| Ezetimibe | Ezetimibe | 143 | 49 |
| Eliquis | Apixaban | 142 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 40 |
| Lorazepam | Lorazepam | 126 | 37 |
| Atenolol | Atenolol | 121 | 35 |
| Jardiance | Empagliflozin | 107 | 35 |
| Prednisone | Prednisone | 107 | 78 |
| Synthroid | Levothyroxine Sodium | 105 | 32 |
| Montelukast Sodium | Montelukast Sodium | 102 | 38 |
| Liothyronine Sodium | Liothyronine Sodium | 98 | 26 |
| Glipizide Er | Glipizide | 90 | 28 |
| Glimepiride | Glimepiride | 89 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 32 |
| Carvedilol | Carvedilol | 86 | 28 |
| Irbesartan | Irbesartan | 82 | 27 |
| Trazodone Hcl | Trazodone Hcl | 78 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 25 |
| Methylprednisolone | Methylprednisolone | 75 | 69 |
| Alendronate Sodium | Alendronate Sodium | 74 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 18 |
| Ozempic | Semaglutide | 73 | 21 |
| Warfarin Sodium | Warfarin Sodium | 68 | 16 |
| Xarelto | Rivaroxaban | 62 | 20 |
| Finasteride | Finasteride | 61 | 22 |
| Trulicity | Dulaglutide | 58 | 11 |
| Celecoxib | Celecoxib | 56 | 26 |
| Fenofibrate | Fenofibrate | 56 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 17 |
| Januvia | Sitagliptin Phosphate | 51 | 16 |
| Meloxicam | Meloxicam | 50 | 23 |
| Dutasteride | Dutasteride | 49 | 16 |
| Famotidine | Famotidine | 47 | 21 |
| Cefdinir | Cefdinir | 46 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Metformin Hcl Er | Metformin Hcl | 46 | 20 |
| Spironolactone | Spironolactone | 46 | 15 |
| Temazepam | Temazepam | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 44 | 40 |
| Donepezil Hcl | Donepezil Hcl | 43 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 20 |
| Valacyclovir | Valacyclovir Hcl | 43 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | 12 |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Ramipril | Ramipril | 38 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | 14 |
| Diazepam | Diazepam | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 13 |
| Propranolol Hcl | Propranolol Hcl | 33 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 29 |
| Amoxicillin | Amoxicillin | 30 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 13 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Jantoven | Warfarin Sodium | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 16 |
| Baclofen | Baclofen | 22 | 13 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | 11 |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 13 |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $375.84 · 13 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, CAPVAXIVE, EVENITY, GARDASIL 9, JARDIANCE, KISUNLA, MOUNJARO, OTEZLA, REPATHA, SIMPLIMAX, TRELEGY ELLIPTA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error